DESCRIPTIVE EPIDEMIOLOGY OF VULVAR MALIGNANCIES IN THE REPUBLIC OF KAZAKHSTAN


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective. To estimate the incidence of vulvar malignancies (VM) in the Republic of Kazakhstan. Material and methods. The investigation material included statistical data on 852 patients registered for VM for the first time across the Republic of Kazakhstan in 2003 to 2012. The source of information was data (death notices and certificates, and autopsy reports) obtained from the specialized and nonspecialized institutions of the country, as well as information from registry offices. Conventional methods of descriptive epidemiology and statistics were applied. Results. A total of 852 patients with newly diagnosed VM were notified during the study period. The largest number of patients with VM (n = 425 (49.9%)) were registered in the oldest age group (70years and older). In the republic, the rough or intense rate of VM incidence was recorded to be 1.0±0.1 (95% CI, 0.9-1.2). Over 10years, the growth rate was 12.6%. There was a geographical variability in the prevalence of VM. Relatively high intense VM incidence rates were recorded in the Northern Central Region (1.4) whereas these in the South Region were equal to 0.9per 100,000 respective population. Over time, the growth rate of VM was 3.9% in the South Region and 6.2% in the Northern Central Region of the Republic of Kazakhstan. Conclusion. Thus, 852 patients with VM were registered in the Republic of Kazakhstan over 10 years. Elderly patients (aged 70 years and older) accounted for half of all the registered. Vulvar cancer showed age-related and geographical variabilities. There were relatively high rates of VM incidence in old age groups and in the Northern Central regions of the country. These results call for further investigations using the analytical epidemiology methods that can explain the geographical variability and identify certain risk factors in the genesis of this relatively rare malignant tumor in women.

全文:

受限制的访问

作者简介

Rush Shalbaeva

Kazakh Research Center of Oncology and Radiology

Email: rash.oncology@mail.ru
MD, a physician-oncogynecologist, oncogynecology center Almaty 0050022, Abay pr. 91, Republic of Kazakhstan

Murad Kayrbaev

Kazakh Research Center of Oncology and Radiology

Email: kairbayev@gmail.com
MD, Head of oncogynecology center Almaty 0050022, Abay pr. 91, Republic of Kazakhstan

参考

  1. Bromfield M.E., Gibson T.N., Hanchard B., Waugh N., McNaughton D. A thirty-year review of vulvar cancer in Jamaica, 1978 to 2007. West Indian Med. J. 2014; 63(2): 134-7.
  2. Арзыкулов Ж.А., Сейтказина Е.Д. Показатели онкологической службы Республики Казахстан за 2011 год (статистические материалы). Алматы; 2012. 150с.
  3. Давыдов М.И., Аксель Е.М., ред. Статистика злокачественных новообразований в России и странах СНГ в 2007 г. Вестник Российского онкологического научного центра им. Н.Н. Блохина РАМН. 2009; 20(3, Приложение №1).
  4. Урманчеева А.Ф. Эпидемиология рака вульвы, факторы риска и прогноза. Практическая онкология. 2006; 7(4): 189-96.
  5. Чиссов В.И., Старинский В.В., Ковалев Б.Н., Петрова Г.В., Грецова О.П., Попова А.А., Харченко Н.В., Данилова Т.В. Стратегия и тактика онкологической службы России на современном этапе. Российский онкологический журнал. 2006; 3: 4-7
  6. Greenlee R.T., Goodman M.T., Lynch C.F., Platz C.E., Havener L.A., Howe H.L. The occurrence of rare cancers in U.S. adults, 1995-2004. Public Health Rep. 2010; 125(1): 28-43.
  7. Chhabra S., Bhavani M., Deshpande A. Trends of vulvar cancer. J. Obstet. Gynaecol. 2014; 34(2): 165-8.
  8. Lai J., Elleray R., Nordin A., Hirschowitz L., Rous B., Gildea C. et al. Vulval cancer incidence, mortality and survival in England: age-related trends. BJOG. 2014; 121(6): 728-38.
  9. Schuurman M.S., van den Einden L.C., Massuger L.F., Kiemeney L.A., van der Aa M.A., de Hullu J.A. Trends in incidence and survival of Dutch women with vulvar squamous cell carcinoma. Eur. J. Cancer. 2013; 49(18): 3872-80.
  10. Akhtar-Danesh N., Elit L., Lytwyn A. Trends in incidence and survival of women with invasive vulvar cancer in the United States and Canada: a population-based study. Gynecol. Oncol. 2014; 134(2): 314-8.
  11. Fuh K.C., Berek J.S. Current management of vulvar cancer. Hematol. Oncol. Clin. North Am. 2012; 26(1): 45-62.
  12. Alkatout I., Schubert M., Garbrecht N., Weigel M.T., Jonat W., Mundhenke C. et al. Vulvar cancer: epidemiology, clinical presentation, and management options. Int. J. Womens Health. 2015; 20(7): 305-13.
  13. McWhirter R.E., Thomson R.J., Marthick J.R., Rumbold A.R., Brown M.A.,Taylor-Thomson D. et al. Runs of homozygosity and a cluster of vulvar cancer in young Australian Aboriginal women. Gynecol. Oncol. 2014; 133(3): 421-6.
  14. Togo-Peraza J.M., Togo-Osuna L.R., Montoya-Romero J.de J. Vulvar carcinoma in situ in 19 year old woman: a case report and literature report. Ginecol. Obstet. Mex. 2014; 82(8): 558-62.
  15. Bodelon C., Madeleine M.M., Voigt L.F., Weiss N.S. Is the incidence of invasive vulvar cancer increasing in the United States? Cancer Causes Control. 2009; 20(9): 1779-82.
  16. Мерабишвили В.М. Злокачественные новообразования в мире, России, Санкт-Петербурге. СПб.: КОСТА; 2007: 9-10.
  17. Chovanec J., Mouková L., Feranec R. Preinvasive lesions in gynecology - vulva. Klin. Onkol. 2013; 26(Suppl.): S44-6.
  18. Baker G.M., Selim M.A., Hoang M.P. Vulvar adnexal lesions: a 32-year, single-institution review from Massachusetts General Hospital. Arch. Pathol. Lab. Med. 2013; 137(9): 1237-46.
  19. Chokoeva A.A., Tchernev G., Castelli E., Orlando E., Verma S.B., Grebe M. et al. Vulvar cancer: a review for dermatologists. Wien. Med. Wochenschr. 2015; 165(7-8): 164-77.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##